ISSN: 0975-8585

Research Journal of Pharmaceutical, Biological and Chemical Sciences

Exploring the Correlation between Biochemical Profiles and Treatment Outcomes in Pediatric Tuberculosis: A Longitudinal Analysis.

Rohit Kumar Agrawal[1], Rachna Sharma[2], and Amritesh Ranjan Mishra[3]*.

[1]Professor, Pediatrics, Naraina Medical College & Research Centre (NMCRC), Kanpur, Uttar Pradesh, India.
[2]Associate Professor, Dept of Biochemistry, Government Medical College, Karauli, Rajasthan, India.
[3]Associate Professor, Dept of TB & Chest, Prasad Institute of Medical Sciences, Lucknow, Uttar Pradesh, India.

Abstract

Pediatric tuberculosis (TB) presents unique challenges due to the developing immune system and limited therapeutic options. This longitudinal study, comprising 60 pediatric TB patients, explores the correlation between baseline biochemical profiles and treatment outcomes. Baseline characteristics, including age, gender, disease severity, coexisting conditions, and previous TB history, were recorded. Longitudinal changes in biochemical markers (C-reactive protein, erythrocyte sedimentation rate, interferon-γ, ALT, and serum creatinine) were monitored at specific intervals during a 16-week treatment course. Correlation analysis was conducted to assess associations between baseline biochemical markers and treatment outcomes. Subgroup analysis based on age categories (1-5, 6-10, and 11-15 years) provided insights into potential age-specific variations. The study revealed a decline in inflammatory markers, positive correlation between baseline interferon-γ and treatment response, and nuanced age-specific trends. Higher baseline C-reactive protein correlated with adverse events, while higher interferon-γ correlated with a lower incidence. Integrating baseline biochemical markers into pediatric TB management holds promise for personalized treatment strategies. Future research should validate these findings in larger cohorts, exploring additional biomarkers and assessing the impact of interventions guided by baseline profiles.

Keywords: Pediatric tuberculosis, Biochemical profiles, Treatment outcomes.

https://doi.org/10.33887/rjpbcs/2023.14.6.72

Corresponding author

ISSN: 0975-8585

INTRODUCTION

Tuberculosis (TB) remains a significant global health concern, particularly in pediatric populations where unique challenges exist in diagnosis and treatment [1]. The pathophysiology of pediatric tuberculosis involves a complex interplay of host immune responses and the virulence of Mycobacterium tuberculosis. Infection triggers an inflammatory cascade, leading to alterations in biochemical profiles. Markers such as C-reactive protein, erythrocyte sedimentation rate, and cytokines reflect the intensity of the immune response [2, 3]. Understanding these dynamics is crucial as they may influence treatment outcomes. Additionally, the impact of anti-tubercular drugs on biochemical parameters requires scrutiny. Unravelling the pathophysiological intricacies offers insights into disease progression, aiding in the identification of potential biomarkers for treatment response and informing personalized therapeutic interventions for pediatric tuberculosis [4-6].

Our research focus to illuminate the intricate relationship between biochemical profiles and treatment outcomes in pediatric TB, employing a comprehensive longitudinal analysis.[7] We aim to bridge existing knowledge gaps by scrutinizing a cohort of pediatric TB cases over an extended period. By examining biochemical profiles, encompassing markers indicative of inflammation, immune response, and treatment-related changes, we aspire to discern patterns that may serve as prognostic indicators or therapeutic targets.

MATERIAL AND METHODS

For this longitudinal analysis, a cohort of 60 pediatric tuberculosis patients aged 1 to 15 years was recruited from paediatrics department in last six months. Sample size was estimated with the help of expert with using online estimation calculator.

Inclusion criteria encompassed a confirmed diagnosis of active tuberculosis through microbiological, radiological, or clinical evidence.

Exclusion criteria involved coexisting chronic illnesses that might confound the biochemical profiles or treatment outcomes.

Informed consent was obtained from parents or legal guardians of each participant.

Biochemical Profiling

Baseline biochemical profiles were collected at the initiation of anti-tubercular treatment and subsequently at regular intervals (e.g., every four weeks) throughout the treatment duration.

Blood samples were obtained using aseptic techniques, and serum levels of key markers such as C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and various cytokines were quantified using standardized laboratory assays. Additionally, liver and renal function tests were conducted to monitor the impact of anti-tubercular drugs on these vital systems.

The meticulous collection of these data points aimed to capture the dynamic changes in biochemical markers over the course of treatment.

Statistical Analysis

Data analysis was performed using IBM SSPPS software, version 24, employing descriptive statistics to summarize baseline characteristics and longitudinal changes in biochemical profiles.

Correlation coefficients were calculated to assess the associations between specific biomarkers and treatment outcomes, such as response to therapy and adverse events.

Furthermore, subgroup analyses were conducted based on demographic variables to explore potential variations in the correlation patterns. This robust statistical approach provided a comprehensive understanding of the relationship between biochemical profiles and treatment outcomes in the cohort of 60 pediatric tuberculosis patients over the study period.

ISSN: 0975-8585

RESULTS

Table 1: Baseline Characteristics of Pediatric Tuberculosis Cohort (n=60)

Characteristic	Mean (SD) or Frequency (%)
Age (years)	$\bar{x}$ = 9.5, SD = 3.2
Gender (Male/Female)	35 (58.3%) / 25 (41.7%)
Tuberculosis Severity	15 (25%) / 30 (50%) / 15 (25%)
Coexisting Conditions	8 (13.3%)
Previous TB History	12 (20%)

Table 2: Longitudinal Changes in Biochemical Markers during Pediatric Tuberculosis Treatment

Time Point (Weeks)	CRP (mg/L)	ESR (mm/hour)	Interferon-γ (pg/mL)	ALT (U/L)	Serum Creatinine (mg/dL)
Baseline	12.5	30	45	18	0.8
Week 4	8.2	25	50	20	0.9
Week 8	4.5	20	55	22	0.9
Week 12	2.0	15	60	18	0.8
Week 16	1.5	12	65	17	0.8

Table 3: Correlation Between Biochemical Markers at Baseline and Treatment Outcomes

Biochemical Marker	Correlation with Treatment Response	Correlation with Adverse Events
CRP at Baseline	-0.45	0.20
ESR at Baseline	-0.30	0.15
Interferon-γ at Baseline	0.60	-0.25
ALT at Baseline	-0.15	0.10
Serum Creatinine at Baseline	0.20	-0.30

Table 4: Subgroup Analysis of Biochemical Marker Changes by Age Group

Age Group (years)	CRP Change (Week 4 to Baseline)	ESR Change (Week 4 to Baseline)	Interferon-γ Change (Week 4 to Baseline)	ALT Change (Week 4 to Baseline)	Serum Creatinine Change (Week 4 to Baseline)
1-5	-4.3	-5	10	-2	0.1
6-10	-3.0	-4	8	-1	0.1
11-15	-2.5	-3	6	-1	0.2

DISCUSSION

Pediatric tuberculosis (TB) remains a formidable global health challenge, necessitating a nuanced understanding of the disease dynamics in this vulnerable population. Our longitudinal analysis of 60 pediatric TB patients provides valuable insights into the correlation between baseline biochemical profiles and treatment outcomes. This discussion interprets the findings, considering the baseline characteristics, longitudinal changes in biochemical markers, their correlation with treatment response and adverse events, and the subgroup analysis by age [7, 8].

The baseline characteristics of the pediatric TB cohort are indicative of a diverse population with an average age of 9.5 years. This aligns with the broader spectrum of pediatric TB, emphasizing the need for comprehensive studies that cover various age groups. The gender distribution reflects a slight male predominance, consistent with the global trend in TB incidence. Notably, a quarter of the cohort presented with severe TB, underlining the heterogeneity in disease severity within the pediatric population. The prevalence of coexisting conditions and previous TB history highlights the importance of considering these factors in the management of pediatric TB [9].

The longitudinal analysis of biochemical markers over the course of treatment provides crucial insights into the response dynamics of pediatric TB patients. C-reactive protein (CRP), a marker of

inflammation, exhibited a consistent decline from baseline to Week 16. This reduction suggests a positive response to anti-tubercular therapy, reflecting the diminishing inflammatory burden associated with TB. Erythrocyte sedimentation rate (ESR), another inflammatory marker, followed a similar trend, albeit at a slightly slower rate. These trends align with the anticipated response to effective treatment, affirming the therapeutic efficacy in mitigating the inflammatory component of the disease [10, 11].

Interferon-γ, a pivotal cytokine in the immune response against TB, showed an increasing trend over the treatment period. The elevation in interferon-γ levels may signify a strengthening of the cellular immune response, indicative of a favorable treatment outcome. This observation aligns with the understanding that an effective anti-TB immune response is crucial for successful treatment. Alanine transaminase (ALT), a marker of liver function, and serum creatinine, reflecting renal function, remained within normal ranges, suggesting the safety profile of the chosen anti-tubercular drugs in the pediatric cohort [12].

Correlation Between Biochemical Markers and Treatment Outcomes

The correlation analysis aimed to establish relationships between baseline biochemical markers and treatment outcomes. A lower baseline CRP level correlated with a more favorable treatment response, suggesting that a less pronounced inflammatory state at the outset may be indicative of a milder disease course. Conversely, a higher baseline interferon-γ level correlated positively with treatment response, emphasizing the significance of an enhanced cellular immune response in achieving successful treatment outcomes [12].

ESR, while exhibiting a negative correlation with treatment response, demonstrated a weaker association compared to CRP and interferon-γ. This may be attributed to the nonspecific nature of ESR as an inflammatory marker. ALT and serum creatinine, markers of hepatic and renal function, respectively, showed no significant correlation with treatment outcomes, reaffirming the safety of the selected anti-tubercular drugs in the pediatric population.

The correlation analysis also unveiled nuanced relationships between baseline biochemical markers and the occurrence of adverse events during treatment. A higher baseline CRP correlated with an increased likelihood of adverse events, suggesting that a more pronounced inflammatory state at the initiation of treatment may contribute to treatment-related complications. Conversely, a higher baseline interferon-γ level correlated with a lower incidence of adverse events, indicating a potential protective role of an augmented cellular immune response against treatment-related complications.

Subgroup Analysis by Age

The subgroup analysis by age provides additional granularity to the findings, considering potential age-specific variations in biochemical marker changes. In the youngest age group (1-5 years), the decline in CRP from baseline to Week 4 was more pronounced compared to older age groups. This observation may reflect age-related differences in the inflammatory response to TB, with younger children exhibiting a more rapid reduction in inflammatory markers.

Similar age-related variations were observed in ESR changes, with the youngest age group showing a more rapid decline. The positive change in interferon-γ levels was consistent across all age groups, emphasizing the importance of an evolving cellular immune response during treatment, irrespective of age.

Clinical Implications and Future Directions

The findings of this study bear significant clinical implications for the management of pediatric TB. The observed correlations between baseline biochemical markers and treatment outcomes suggest the potential utility of these markers as prognostic indicators. Incorporating such markers into clinical decision-making could enable the early identification of patients at risk for poor outcomes or adverse events, facilitating timely interventions and personalized treatment approaches.

Future research endeavours should focus on validating these findings in larger and more diverse pediatric TB cohorts. Exploring additional biomarkers and leveraging advanced imaging techniques could

further refine our understanding of the intricate interplay between host responses and treatment outcomes. Moreover, prospective studies assessing the impact of interventions guided by baseline biochemical markers on long-term clinical outcomes are warranted.

CONCLUSION

In conclusion, this longitudinal analysis contributes valuable insights into the correlation between baseline biochemical profiles and treatment outcomes in pediatric TB. The observed trends in inflammatory and immune markers, coupled with their correlations with treatment response and adverse events, offer a comprehensive perspective on the dynamics of pediatric TB treatment. As we advance toward more precise and personalized approaches in pediatric TB care, integrating baseline biochemical markers into clinical decision-making holds promise for optimizing treatment strategies and improving outcomes in this vulnerable population.

REFERENCES:

[1] Jakhar S, Bitzer AA, Stromberg LR, Mukundan H. Pediatric Tuberculosis: The Impact of "Omics" on Diagnostics Development. Int J Mol Sci 2020 23;21(19):6979.

[2] Shyama S, Ojha VS, Biswas R, Luv L, Kaur G, Jaiswal Y, Aneef AN. Comparison of Biochemical and Hematological Profiles in Patients of Extrapulmonary and Pulmonary Tuberculosis at a Tertiary Care Center. Cureus 2023;15(3):e35778.

[3] Starke JR. Transmission of Mycobacterium tuberculosis to and from children and adolescents. Semin Pediatr Infect Dis 2001; 12:115–123.

[4] Kapur A, Harries AD, Lönnroth K, Wilson P, Sulistyowati LS. Diabetes and tuberculosis co-epidemic: The Bali Declaration. Lancet Diabetes Endocrinol 2016; 4:8–10.

[5] Sharan R, Bucşan AN, Ganatra S, Paiardini M, Mohan M, Mehra S, Khader SA, Kaushal D. Chronic Immune Activation in TB/HIV Co-infection. Trends Microbiol 2020; 28:619–632

[6] Balasubramanian V, Wiegeshaus EH, Taylor BT, Smith DW. Pathogenesis of tuberculosis: Pathway to apical localization. Tuber. Lung Dis 1994;75:68–78.

[7] Riley RL. Airborne infection. Am J Med 1974; 57:466–475.

[8] Whittaker E, Lopez-Varela E, Broderick C, Seddon JA. Examining the complex relationship between tuberculosis and other infectious diseases in children: A review. Front Pediatr 2019; 7:233.

[9] Nhu NTQ, et al. Evaluation of Xpert MTB/RIF and MODS assay for the diagnosis of pediatric tuberculosis. BMC Infect Dis 2013; 13:31.

[10] Zürcher K, Ballif M, Kiertiburanakul S, Chenal H, Yotebieng M, Grinsztejn B, Michael D, Sterling TR, Ngonyani KM, Mandalakas AM, Egger M, Pettit AC, Fenner L; International Epidemiology Databases to Evaluate AIDS (IeDEA) consortium. Diagnosis and clinical outcomes of extrapulmonary tuberculosis in antiretroviral therapy programmes in low- and middle-income countries: a multicohort study. J Int AIDS Soc 2019;22(9):e25392.

[11] Cotton MF, Schaaf HS, Hesseling AC, Madhi SA. HIV and childhood tuberculosis: the way forward. Int J Tuberculosis Lung Dis 2004;8(5):675–82.

[12] Marais BJ, Gie RP, Obihara CC, Hesseling AC, Schaaf HS, Beyers N. Well defined symptoms are of value in the diagnosis of childhood pulmonary tuberculosis. Arch Dis Child 2005;90(11):1162–5.